Jpmorgan Chase & CO Aerovate Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 75,674 shares of AVTE stock, worth $202,806. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75,674
Previous 67,165
12.67%
Holding current value
$202,806
Previous $177,000
6.78%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AVTE
# of Institutions
12Shares Held
4.48MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY983KShares$2.63 Million0.0% of portfolio
-
Morgan Stanley New York, NY699KShares$1.87 Million0.0% of portfolio
-
Oup Management Co., LLC604KShares$1.62 Million18.43% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL40KShares$107,3250.0% of portfolio
-
Kovitz Investment Group Partners, LLC24.2KShares$64,8820.0% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $65.5M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...